Precision Prostate Cancer Treatment Using MRI Radiomics and AI

Prostate cancer is one of the most common cancers in men worldwide. Stereotactic Ablative Body Radiotherapy (SABR) provides a precise and effective treatment option, delivered in fewer sessions compared to conventional radiation therapy. While SABR has demonstrated high five-year tumor control rates, the risk of local recurrence increases over time, and current monitoring relies on periodic blood tests, which may not detect early signs of recurrence.

To address these challenges, our team is advancing precision radiation therapy for prostate cancer through the Biologically Targeted Radiation Therapy (BiRT) project. Our goal is to personalize treatment by mapping the patient-specific spatial distribution of cancer using advanced imaging techniques such as multiparametric MRI and PET/CT. Towards this goal we have been running a clinical trial to develop quantitative MRI and radiomics-based biomarkers, which can assess early response to SABR more accurately than standard blood testing. The development of robust imaging biomarkers would enable early interventions that target radio-resistant disease, to limit the risk of disease progression.

• A Bachelors degree in Engineering, Computer Science, Mathematics, Physics or related discipline

• Strong image processing and programming skills

• Excellent verbal and written communication skills

• Ability to work on their own and as part of a team
  

Page expires: 18 December 2024